2[1]Lam KY, Lo CY, Fan ST, et al. Telomerase activity in pancreatic endocrine tumours: a potential marker for malignancy[J]. Mol Pathol, 2000,53(3): 133-136.
3[2]Wu A, Ichihashi M, Ueda M. Correlation of the expression of human telomerase subunits with telomerase activity in normal skin and skin tumors[J]. Cancer, 1999,86(10): 2038-2044.
4[3]Kim NW, Wu F. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP)[J]. Nucleic Acid Res, 1997,25(6): 2595-2602.
5[4]Ramirez RD, D Atri S, Pagani E, et al. Progressive increase in telomerase activity from benign melanocytic conditions to malignant melanoma[J]. Neoplasia, 1999,1(1): 42-49.
6[5]Lichtsteiner SP, Lebkowski JS, Vasserot AP. Telomerase. A target for anticancer therapy[J]. Ann N Y Acad Sci, 1999,886(1): 1-11.
7[6]Rha SY, Izbicka E, Lawrence R, et al. Effect of telomere and telomerase interactive agents on human tumor and normal cell lines[J]. Clin Cancer Res, 2000,6(3): 987-993.
8[7]Daniel EG, Tejera AM, Olive OA. Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine (AZT) treatment[J]. Biochem Biophy Res Commun, 1998,246(1): 107-110.
9[8]Zhu XL, Kumar R, Mandal M, et al. Cell cycle-dependent modulation of telomerase activity in tumor cells[J]. Proc Natl Acad Sci USA, 1996,93(7): 6091-6095.
